CD274 and non-small cell lung carcinoma: The advent of immune checkpoint inhibitors (ICIs), targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1), has revolutionized cancer therapy, demonstrating durable responses in advanced-stage NSCLC [7,8].